post-cal model adjust new product beyond
make minor updat estim zoeti follow compani strong
fourth-quart earn releas thursday morn februari overal fourth-
quarter number ahead estim full-year ep guidanc midpoint
line target revenu expect better expect
off-set margin headwind
believ key stock driver increasingli abil gener organ revenu
growth excess anim health market midsingle-digit trend line simparica trio
import new contributor beyond follow new biolog
companion anim pain next year given impress pace innov
compani team believ compani continu outpac broader
market thu maintain outperform rate despit recent expans
companion anim investor attent larg focus potenti
simparica trio apoquel cytopoint combin million revenu
fourth quarter year-over-year increas see exhibit dermatolog
growth rate like slow believ ampl opportun drive addit
growth oversea parasiticid manag repeat goal simparica trio
contribut million increment revenu year lift total revenu
product alreadi approv eu canada stock appar begun
market unit state manag suggest launch week
approv reason suggest materi contribut second
quarter compani potenti becom top-tier player parasiticid
opinion assum uptak robust expect
return equiti ttm
zoeti leader develop manufactur market anim health medicin vaccin
product companion anim market annual revenu exceed billion compani found
divis spun februari oper countri maintain one
largest budget industri
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
exhibit companion anim organ growth geographi present
exhibit quarterli apoquel cytopoint sale present
livestock though expect livestock lag overal anim health market manag commentari
recent product introduct continu invest segment give us confid compani grow
busi rang longer term roughli point believ market rate
 cattl dairi condit remain challeng present believ enough growth poultri plu
stabil swine come year allow increas exhibit
exhibit livestock organ growth speci present
xxsourc compani report william blair compani compani report william blair william blair
exhibit livestock organ growth geographi present
increas revenu estim million billion target organ
growth compar previous maintain ep estim reflect notabl higher
interest expens year along higher share count
view follow key risk zoeti next three five year delay simparica trio approv
unit state would caus companion anim sale fall short expect next year slowdown
economi neg affect spend companion anim livestock diseas outbreak shift away
usag antibiot food anim shift away meat consumpt develop market due chang
valuat stock thought
zoeti trade time unchang ep estim compar post-ipo averag time
forward earn anim health manufactur peer time high-growth diagnost peer time
continu impress manag steadi execut steadi flow novel product result
reiter outperform rate despit valuat limit room expans summari revis
model found exhibit
xxsourc compani report william blair william blair
good gross gener research amort intang total oper oper expense/ incom pre-tax tax net loss attribut non-controlling interest- net incom excl non-recurring non-recurring item net net ep excl non-recurring per average share outstand margin analysi gross metric total revenu constant oper revenu constant incom excl non-recur excl non-recur share blair compani estimatesourc compani report william blair compani llc estim import disclosur
william blair affili market maker secur zoeti inc
william blair affili expect receiv intend seek compens invest bank servic zoeti inc affili
within next three month
offic employe william blair affili research analyst may financi interest secur zoeti
inc report avail electron form regist user via doc http //williamblairlibrari bluematrix com
pleas contact us consult williamblair com/research-and-insights/equity-research/coverag aspx disclosur
